NIH Begins Study of Vaccine to Protect Against Mosquito-Borne Diseases

Experimental Vaccine Targets Mosquito Saliva

National Institute of Allergy and Infectious Diseases (NIAID), February 21, 2017

Read online at:
https://www.niaid.nih.gov/news-events/nih-begins-study-vaccine-protect-against-
mosquito-borne-diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has launched a Phase 1 clinical trial to test an investigational vaccine intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability of mosquitoes to transmit such infections. Unlike other vaccines targeting specific mosquito-borne diseases, the AGS-v candidate is designed to trigger an immune response to mosquito saliva rather than to a specific virus or parasite carried by mosquitoes. The test vaccine contains four synthetic proteins from mosquito salivary glands. The proteins are designed to induce antibodies in a vaccinated individual and to cause a modified allergic response that can prevent infection when a person is bitten by a disease-carrying mosquito.

(Visited 13 times, 1 visits today)
This entry was posted in Essential Medicines, General, Other Infectious Diseases. Bookmark the permalink.